文献速递哮喘

低呼出气一氧化氮水平排除疑似哮喘患者短期吸入糖皮质激素获益

A low exhaled nitric oxide level excludes a short-term benefit from inhaled corticosteroids in suspected asthma: A randomized placebo-controlled trial.
PubMed 文献 · Respirology · 2021-05-03

本研究为随机安慰剂对照试验,纳入180例未经激素治疗、疑似哮喘且FeNO≤27 ppb的成人,随机接受布地奈德400 mcg每日或安慰剂治疗3个月。主要结局ACQ7组间差异为-0.25(95%CI -0.004至0.495),证实等效性(p<0.05),FEV1等次要结局差异亦小且无临床重要性。结论提示此类患者启动ICS治疗3个月不太可能获益,但建议进一步研究确认后再决定是否 withhold ICS。

要点

  • 疑似哮喘且FeNO≤27 ppb的未经激素治疗成人,启动布地奈德400 mcg/日治疗3个月与安慰剂等效。
  • ACQ7组间差异-0.25(95%CI -0.004至0.495),FEV1等次要结局差异小且无临床重要性。
  • 建议进一步研究确认后,再考虑对此类患者不启动ICS治疗。

核心结论

  • 疑似哮喘且FeNO≤27 ppb的未经激素治疗患者,启动ICS治疗3个月不太可能获益。
  • 建议进一步研究确认后再 withholding ICS治疗。

研究设计与样本

  • 随机安慰剂对照试验,180例未经激素治疗、疑似哮喘且FeNO≤27 ppb的成人随机接受布地奈德400 mcg每日或安慰剂治疗3个月。
  • 主要结局为ACQ7组间差异,研究设计为等效性检验。

主要发现

  • ACQ7从基线至研究结束的组间平均差异为-0.25,95%CI -0.004至0.495,证实等效性(p<0.05)。
  • FEV1及其他次要结局差异亦小且无临床重要性。

关键数值与推荐

  • FeNO≤27 ppb为入组阈值。
  • 布地奈德剂量为400 mcg每日,疗程3个月。
  • ACQ7组间差异-0.25(95%CI -0.004至0.495,p<0.05)确认等效。

临床怎么用

  • 对疑似哮喘且FeNO≤27 ppb的未经激素治疗成人,可考虑不启动ICS治疗。
  • 需进一步研究确认后再将此策略用于临床决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Fractional exhaled nitric oxide (FeNO) is a non-invasive biomarker that reflects IL-4/IL-13 production and therefore represents T2 allergic inflammation. FeNO has previously been used to guide inhaled corticosteroid (ICS) treatment in asthma. The purpose of this study was to determine if a low FeNO (≤27 ppb) could be used to reliably identify patients with symptoms suggestive of asthma who would not benefit from initiating treatment with an ICS. METHODS: A total of 180 steroid-naïve adults with healthcare professional suspected asthma and an FeNO of ≤27 ppb were randomized to receive either 400 mcg of budesonide or placebo daily for 3 months. The primary outcome was the difference in the Asthma Control Questionnaire 7 (ACQ7) between treatment groups and the study was powered to determine equivalence. Secondary outcomes were the difference in FEV1 , Medical Research Council and Leicester Cough Questionnaire scores. RESULTS: One hundred and thirty-four patients (68 budesonide and 66 placebo) completed the study and were included in the analysis. The between-group mean difference in ACQ7 from baseline to the end of the study was -0.25 and the 95% CI around this difference was -0.004 to 0.495 confirming equivalence (p < 0.05). Differences in forced expiratory volume over 1 s and other secondary outcomes were also small and clinically unimportant. CONCLUSION: The results of this study suggest that steroid-naïve patients with symptoms suggestive of asthma and an FeNO ≤ 27 ppb are unlikely to benefit from initiating treatment with an ICS over 3 months. However, further research is recommended to confirm these findings before withholding ICS treatment.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Sutherland L, Shaw K, Parrish C, et al. A low exhaled nitric oxide level excludes a short-term benefit from inhaled corticosteroids in suspected asthma: A randomized placebo-controlled trial. Respirology. 2021. PMID: 33939245. doi:10.1111/resp.14055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。